


Senegal ALMA Quarterly Report

Quarter Four, 2025



Scorecard for Accountability and Action



Metrics

Policy

Signed, ratified and deposited the AMA instrument at the AUC		
Malaria activities targeting refugees in Malaria Strategic Plan		
Malaria activities targeting IDPs in Malaria Strategic Plan		
Zero Malaria Starts With Me Launched		
End Malaria Council and Fund Launched		

Resistance Monitoring, Implementation and Impact

Drug efficacy studies conducted since 2019 and data reported to WHO		
Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010		5
Insecticide resistance monitored since 2020 and data reported to WHO		
% of vector control in the last year with next generation materials		99
ACTs in stock (>6 months stock)		
RDTs in stock (>6 months stock)		
On track to reduce malaria incidence by at least 75% by 2025 (vs 2015)	▲	
On track to reduce malaria mortality by at least 75% by 2025 (vs 2015)	▲	

Tracer Indicators for Maternal and Child Health and NTDs

Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2024)		71
% of Neglected Tropical Disease MDAs Achieving WHO Targets		60
National Budget Allocated to NTDs		
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2024)		65
DPT3 coverage 2024 (vaccination among 0-11 month olds)		91
Climate Change and VBDs in NDCs		

Key



- Target achieved or on track
- Progress but more effort required
- Not on track
- No data
- Not applicable

The annual reported number of malaria cases in 2024 was 499,675 and 301 deaths.

Malaria - The Big Push towards 2030

Africa is at the centre of a perfect storm that threatens to disrupt malaria services and undo decades of progress. Countries must act urgently to both prevent and mitigate the adverse effects of the ongoing global financial crisis, decreasing ODA, increasing biological threats, climate change, and humanitarian crises. These threats represent the most serious emergency facing malaria in 20 years and will lead to malaria upsurges and epidemics if not addressed. To get back on track and eliminate malaria, US\$5.2 billion is needed annually to fully finance country national malaria plans, and urgently fill gaps created by the recent reductions in ODA. Extreme weather events and climate change present a significant threat. Africa is disproportionately exposed to the risks of climate change and by the 2030s, 150 million additional people will be at risk of malaria because of warmer temperatures and increased rainfall. Extreme weather events displace millions and destroy roads and health facilities, reducing access to health services. Countries must also take action to confront the threats of insecticide and drug resistance, reduced efficacy of rapid diagnostic tests, and the invasive *Anopheles stephensi* mosquito which spreads malaria in both urban and rural areas. The good news is that the malaria toolkit continues to expand. WHO has approved the use of dual-insecticide mosquito nets that are 43% more effective than traditional mosquito nets and will address the impact of insecticide-resistance. New medicines for treating malaria and two malaria vaccines for children have also been approved with an increasing number of countries deploying these new tools. Malaria can serve as a pathfinder for primary health care strengthening, climate change and health, and Universal Health Coverage. Countries must work to sustain and increase domestic resource commitments including through multisectoral End Malaria and NTD Councils and Funds, which have raised over US\$181 million to date.

A recent report by ALMA and MNM UK, "The Price of Retreat," highlights the expected impact of malaria between 2025-2030 on GDP, trade and key sectors for development in Africa. If Senegal cannot sustain malaria prevention due to reductions in malaria financing, this would lead to an estimated 3,552,227 additional cases, 9,188 more deaths, and GDP loss of US\$347.2 million between 2025 and 2030. However, if we mobilise the necessary resources and achieve a 90% reduction in malaria, in Senegal there will be a US\$964.5 million increase in GDP.

Progress

Senegal has carried out insecticide resistance monitoring since 2015 and has reported the results to WHO, and in response to the identified insecticide resistance has scaled up next generation mosquito nets. The country has also carried out drug resistance testing. Senegal was the first country to launch the Zero Malaria Starts with Me campaign.

In line with the priority agenda of the ALMA chair, President Advocate Duma Gideon Boko, Senegal has significantly enhanced the tracking and accountability mechanisms for malaria with the development of a Malaria Control and Elimination Scorecard, although the scorecard has not yet been posted to the ALMA Scorecard Hub. The country should consider establishing an End Malaria Council and Fund to enhance domestic resource mobilization and multi-sectoral action.

Impact

The annual reported number of malaria cases in 2024 was 499,675 and 301 deaths.

Key Challenge

- Insufficient resources to fully implement the malaria national strategic plan, including with the impact of recent reductions in ODA

The country has responded positively to previous recommended action on drug resistance monitoring and is working to implement the actions.

New Key Recommended Action

Objective	Action Item	Suggested completion timeframe
Impact	Work to ensure that malaria elimination is prioritised in the America First Global Health Strategy Country Memorandum of Understanding, and that costed prioritised plans are developed	Q1 2026

Reproductive, Maternal, Newborn, Adolescent and Child Health

Progress

Senegal has achieved high coverage of BPT3. The country has enhanced the tracking and accountability mechanisms with the development of the Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard.

Neglected Tropical Diseases

Progress

Progress in addressing Neglected Tropical Diseases (NTDs) in Senegal is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, onchocerciasis, schistosomiasis, soil transmitted helminths and trachoma. In 2024, preventive chemotherapy coverage was 100% for trachoma, for onchocerciasis and for lymphatic filariasis (under surveillance). It was 70% for schistosomiasis and 25% for soil transmitted helminths. Overall, the NTD preventive chemotherapy coverage index for Senegal in 2024 is 71. The country didn't reach WHO MDA targets for schistosomiasis and soil transmitted helminthiasis in 2024. Senegal has included Vector-borne diseases in the country Nationally Determined Contributions and has created an NTD budget line.

Key

	Action achieved
	Some progress
	No progress
	Deliverable not yet due